Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Additional Features in the Treatment of Patients with Chronic Heart Failure. From EMPA-REG OUTCOME Study to EMPEROR-REDUCED Study. Resolution of the On-line Scientific Meeting of Moscow Experts

https://doi.org/10.20996/1819-6446-2021-01-03

Full Text:

Abstract

The results of the international multicenter study EMPEROR-REDUCED were reviewed the on-line scientific meeting of Moscow experts on October 30, 2020. Some proposals and recommendations for further study of the cardiovascular and renal effects of empagliflozin and its use in clinical practice in patients with chronic heart failure with reduced ejection fraction were accepted.

About the Authors

A. Yu. Lebedeva

Russian Federation

Anastasia Yu. Lebedeva

eLibrary SPIN: 5700-5075



O. M. Koteshkova

Russian Federation

Olga M. Koteshkova

eLibrary SPIN: 6141-1224



O. N. Dzhioeva

Russian Federation

Olga N. Dzhioeva

eLibrary SPIN: 1803-5454



S. R. Gilyarevsky

Russian Federation

Sergey R. Gilyarevsky

eLibrary SPIN: 1683-2709



T. M. Uskach

Russian Federation

Tatiana M. Uskach

eLibrary SPIN: 8752-9657



M. S. Novikova

Russian Federation

Maria S. Novikova

eLibrary SPIN: 5227-0554



Ya. A. Orlova

Russian Federation

Yana A. Orlova

eLibrary SPIN: 3153-8373



V. Yu. Kalashnikov

Russian Federation

Victor Yu. Kalashnikov

eLibrary SPIN: 5342-7253



D. V. Privalov

Russian Federation

Dmitry V. Privalov



N. A. Ananicheva

Russian Federation

Natalia A. Ananicheva

eLibrary SPIN: 2247-0561



M. Yu. Gilyarov

Russian Federation

Mikhail Yu. Gilyarov

eLibrary SPIN: 7713-6726



A. D. Erlikh

Russian Federation

Alexey D. Erlikh

eLibrary SPIN: 4697-0822



References

1. Koudstaal S., Pujades-Rodriguez M., Denaxas S., et al. Prognostic burden of heart failure recorded in primary care, acute hospital admissions, or both: a population-based linked electronic health record cohort study in 2.1 million people. Eur J Heart Fail. 2017;19(9):1119-27. DOI:10.1002/ejhf.709.

2. Jones N.R., Roalfe A.K., Adoki I., et al. Survival of patients with chronic heart failure in the community: a systematic review and meta-analysis. Eur J Heart Fail. 2019;21(11):1306-25. DOI:10.1002/ejhf.1594.

3. Zinman B., Wanner C., Lachin J.M., et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-28. DOI:10.1056/NEJMoa1504720.

4. Wanner C., Inzucchi S.E., Lachin J.M., et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375(4):323-34. DOI:10.1056/NEJMoa1515920.

5. Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care 2020;43:508-11. DOI:10.2337/dci19-0074.

6. Packer M., Anker S.D., Butler J., et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020;383(15):1413-24. DOI:10.1056/NEJMoa2022190.

7. Packer M., Anker S.D., Butler J., et al. Effect of Empagliflozin on the Clinical Stability of Patients with Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Circulation. 2020 Oct 21. DOI:10.1161/CIRCULATIONAHA.120.051783.

8. Instructions for the medical use of Jardins® LP-002735 [cited 10/01/2020]. Available at: http://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=74ca831d-640f-4bcf-ae60-b17253a6d72d&t= (In Russ.)


For citation:


Lebedeva A.Yu., Koteshkova O.M., Dzhioeva O.N., Gilyarevsky S.R., Uskach T.M., Novikova M.S., Orlova Ya.A., Kalashnikov V.Yu., Privalov D.V., Ananicheva N.A., Gilyarov M.Yu., Erlikh A.D. Additional Features in the Treatment of Patients with Chronic Heart Failure. From EMPA-REG OUTCOME Study to EMPEROR-REDUCED Study. Resolution of the On-line Scientific Meeting of Moscow Experts. Rational Pharmacotherapy in Cardiology. 2021;17(1):165-168. (In Russ.) https://doi.org/10.20996/1819-6446-2021-01-03

Views: 148


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)